FINACEA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FINACEA (FINACEA).
Azelaic acid inhibits microbial protein synthesis, reduces reactive oxygen species production, and modulates keratinocyte and melanocyte function.
| Metabolism | Azelaic acid is not extensively metabolized; a small portion undergoes beta-oxidation. Eliminated mainly via renal excretion. |
| Excretion | Renal: primarily as unchanged drug (minimal metabolism); approximately 16% of a topical dose is absorbed and excreted renally; fecal excretion is negligible. |
| Half-life | Not determined clinically due to negligible systemic absorption; after topical application, plasma levels are below quantification limits; no terminal half-life is established. |
| Protein binding | Not applicable due to minimal systemic absorption; if absorbed, azelaic acid is not significantly protein bound. |
| Volume of Distribution | Not applicable for topical route; systemic absorption is too low to compute Vd. |
| Bioavailability | Topical: approximately 3.6% of a 20% cream dose is absorbed percutaneously; oral bioavailability is low due to extensive first-pass metabolism (not used orally). |
| Onset of Action | Topical: clinical improvement in inflammatory lesions of rosacea may be observed within 4 weeks of twice-daily application. |
| Duration of Action | Topical: continuous twice-daily application is required to maintain reduction in inflammatory lesions; effects diminish upon discontinuation. |
Apply a pea-sized amount topically twice daily (morning and evening) to affected areas of the face.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not approved for use in pediatric patients under 18 years of age; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use caution due to increased potential for skin irritation in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FINACEA (FINACEA).
| Breastfeeding | M/P ratio not established. Azelaic acid is excreted in human milk at low concentrations. Caution should be exercised when administered to a nursing woman. Decision to discontinue nursing or drug should consider importance of drug to mother. |
| Teratogenic Risk | Pregnancy Category B. Animal studies show no evidence of impaired fertility or harm to fetus. No adequate well-controlled studies in pregnant women. Azelaic acid is not expected to be teratogenic; however, systemic absorption following topical application is minimal (approximately 4%). Risk in first trimester is negligible; use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to azelaic acid or any component of the formulation.
| Precautions | Hypopigmentation (may occur with prolonged use); local irritation; caution in asthma. Discontinue if hypersensitivity occurs. |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Periodic skin assessment for local reactions. No systemic toxicity monitoring indicated due to minimal absorption. For pregnant women, routine prenatal care suffices. |
| Fertility Effects | No adverse effects on fertility observed in animal studies. No human data available. Azelaic acid does not affect reproductive organs or hormone levels. Clinically, no impact on male or female fertility expected. |